Embecta (NASDAQ:EMBC) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS

Embecta (NASDAQ:EMBC) released its quarterly earnings data on Friday. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.29, Zacks reports. Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The company had revenue of $271.70 million during the quarter, compared to analyst estimates of $254.53 million. During the same quarter in the previous year, the business posted $1.12 EPS. Embecta’s revenue for the quarter was down 8.1% compared to the same quarter last year. Embecta updated its FY 2026 guidance to 1.800-1.900 EPS.

Here are the key takeaways from Embecta’s conference call:

• U.S. revenue fell 24.6% year over year to approximately $121 million, reflecting weaker insulin-pen prescription trends, customer and payer mix pressure, and prior-year one-time benefits. Management said its outlook assumes no further recovery or deterioration in these market factors.
• Third-quarter revenue declined 8.1% year over year to approximately $272 million, although it improved sequentially by roughly $50 million. International revenue rose 11.5% as reported, helping offset continued U.S. weakness and anticipated softness in China.
• Owen Mumford integration is progressing as planned, adding auto-injectors, pharmaceutical services, and medical devices. Embecta sees a roughly $2.4 billion auto-injector market growing at a double-digit rate, though it is not yet providing specific revenue expectations for the Adaptis platform.
• Embecta raised fiscal 2026 adjusted operating margin guidance to 23.5%–24% from 22.25%–23.25% and adjusted EPS guidance to $1.80–$1.90 from $1.55–$1.75, citing cost controls, lower taxes and interest expense, and share repurchases.
• The company generated approximately $41 million in third-quarter free cash flow, repaid $53 million of debt, and expects to repay at least $150 million during fiscal 2026. Management said continued debt reduction will remain the primary capital-allocation priority.

Embecta Stock Up 26.3%

EMBC stock opened at $4.42 on Friday. Embecta has a twelve month low of $2.77 and a twelve month high of $15.55. The stock’s 50 day moving average is $3.34 and its 200-day moving average is $6.66. The firm has a market capitalization of $262.24 million, a PE ratio of 2.99 and a beta of 0.81.

Embecta Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th will be paid a $0.01 dividend. The ex-dividend date of this dividend is Thursday, August 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.9%. Embecta’s dividend payout ratio is 2.11%.

Embecta News Summary

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates: Embecta reported adjusted EPS of $0.56, exceeding the $0.27 consensus estimate, while revenue of $271.7 million topped expectations of $254.5 million. Embecta Q3 earnings report
• Positive Sentiment: Full-year EPS outlook raised: Management provided fiscal 2026 EPS guidance of $1.80–$1.90, above the $1.60 analyst consensus, signaling stronger expected profitability despite business pressures. Embecta fiscal 2026 results
• Positive Sentiment: Dividend maintained: Embecta declared a quarterly cash dividend of $0.01 per share, providing a modest continuing shareholder return. Embecta dividend announcement
• Neutral Sentiment: Strategic diversification: Embecta reiterated its plan to expand beyond insulin delivery into a broader medical-supplies business. The strategy could create longer-term growth opportunities, but the release provided limited detail on execution or near-term returns. Embecta company announcement
• Negative Sentiment: Sales remain under pressure: Quarterly revenue fell 8.1% year over year to $271.7 million, and EPS declined from $1.12 in the comparable period. This highlights ongoing weakness in Embecta’s core operations even with the earnings beat. Embecta earnings details
• Negative Sentiment: Securities-fraud lawsuit adds risk: Multiple law firms publicized a class action alleging Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business. The August 17 lead-plaintiff deadline increases visibility around potential legal costs, damages and reputational risk. Embecta securities-fraud lawsuit notice

Institutional Investors Weigh In On Embecta

Institutional investors have recently bought and sold shares of the stock. Larson Financial Group LLC raised its position in Embecta by 368.6% in the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after buying an additional 1,574 shares during the last quarter. Wexford Capital LP bought a new position in Embecta during the 3rd quarter valued at $94,000. Tower Research Capital LLC TRC boosted its holdings in Embecta by 542.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after acquiring an additional 6,224 shares during the last quarter. iSAM Funds UK Ltd purchased a new position in Embecta during the 3rd quarter worth $115,000. Finally, Amundi bought a new stake in shares of Embecta in the 4th quarter worth $127,000. Institutional investors own 93.83% of the company’s stock.

Analysts Set New Price Targets

EMBC has been the subject of several research analyst reports. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Mizuho cut their price objective on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Wall Street Zen downgraded Embecta from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings lowered Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Embecta currently has an average rating of “Reduce” and an average price target of $11.00.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.